TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06778850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDR-001
Description: Oral administration of small molecule MDR-001 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDR-001
Description: Oral administration of small molecule MDR-001 tablets
Study: NCT04805736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Surgery
Description: Standard of care breast conserving surgery or radical mastectmoy
Study: NCT06778850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palcebo
Description: Administered orally placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palcebo
Description: Administered orally placebo
Study: NCT06778590

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezoelectric technique in third molar germectomy
Description: Application of piezoelectric technique in third molar germectomy procedures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional technique in third molar germectomy
Description: Application of traditional technique in third molar germectomy procedures
Study: NCT06778603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a targeted probe B7H3-IRDye800CW
Description: B7H3-IRDye800CW was synthesized by conjugating IRDye800CW NHS Ester and Anti-B7H3 antibody.
Study: NCT06779643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Description: Anesthesia induction will be achieved using propofol (1.5-2 mg/kg i.v.), rocuronium (1-2 mg/kg i.v.), and fentanyl (1-2 μg/kg i.v.). Anesthesia will be maintained using sevoflurane or desflurane, with inhaled concentration adjusted based on Bispectral Index (BIS) monitoring. A continuous infusion of remifentanil (0.05-0.2 μg/kg/min) will be administered, with adjustments to maintain blood pressure and heart rate within ±20% of baseline values. Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode. The ventilator (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) settings will be: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cm H2O, inspiratory to expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and fraction of inspired oxygen 41%.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Description: Anesthesia induction will be achieved using propofol (1.5-2 mg/kg i.v.), rocuronium (1-2 mg/kg i.v.), and fentanyl (1-2 μg/kg i.v.). Anesthesia will be maintained using sevoflurane or desflurane, with inhaled concentration adjusted based on Bispectral Index (BIS) monitoring. A continuous infusion of remifentanil (0.05-0.2 μg/kg/min) will be administered, with adjustments to maintain blood pressure and heart rate within ±20% of baseline values. Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode. The ventilator (Aestiva; GE Healthcare, Waukesha, Wisconsin, USA) settings will be: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cm H2O, inspiratory to expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and fraction of inspired oxygen 41%.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Brachial Plexus Block
Description: Patients were positioned supine with the head slightly turned to the contralateral side to expose the supraclavicular fossa. The injection site was prepared using standard aseptic techniques. Under ultrasound guidance, a needle was advanced to the vicinity of the brachial plexus. Aspiration was performed to confirm the absence of blood return before the slow, incremental injection of either liposomal bupivacaine \[adult dose: 133 mg (10 mL) to 266 mg (20 mL)\] or ropivacaine \[adult dose: 20 mL of 0.5% ropivacaine, administered via continuous infusion at a rate of 5-10 mL/h; pediatric dose: 0.1% ropivacaine at 0.1-0.2 mL/kg, administered via continuous infusion at 0.05-0.15 mL/kg/h\]. Patient responses were closely monitored throughout the procedure.
Study: NCT06777680

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: co-ultramicronized Palmitoylethanolamide + Luteolin (770 mg)
Description: oral suspension, 10 ml twice a day (every 12 hours) for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral suspension,10 ml twice a day (every 12 hours) for 7 days

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Thrombectomy
Description: Endovascular Thrombectomy in all eligible patients, according to national acute stroke treatment guidelines
Study: NCT06279949

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic protocols
Description: Clinics randomized to a condition involving the implementation of new clinic protocols to support confidential care provision will receive training on navigating the new protocols.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic protocols
Description: Clinics randomized to a condition involving the implementation of new clinic protocols to support confidential care provision will receive training on navigating the new protocols.
Study: NCT06777680

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombectomy
Description: Endovascular Thrombectomy in all eligible patients, according to national acute stroke treatment guidelines
Study: NCT06777589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring of anesthesia depth
Description: During gastroscopy and colonoscopy procedures, the Bispectral Index Monitor (Apollo-9000A) is utilized to monitor patients' quantitative consciousness index (qCON) and quantitative nociception index (qNOX).
Study: NCT05985915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ianalumab (VAY736)
Description: Ianalumab 300 mg / 2 mL, PFS or AI, monthly or every 3 months, solution for injection for subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ianalumab (VAY736)
Description: Ianalumab 300 mg / 2 mL, PFS or AI, monthly or every 3 months, solution for injection for subcutaneous use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 0 mg/2 mL PFS or AI, once monthly between doses of Ianalumab 3 monthly , solution for injection for subcutaneous Use
Study: NCT06777589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring of anesthesia depth
Description: During gastroscopy and colonoscopy procedures, the Bispectral Index Monitor (Apollo-9000A) is utilized to monitor patients' quantitative consciousness index (qCON) and quantitative nociception index (qNOX).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring of anesthesia depth
Description: During gastroscopy and colonoscopy procedures, the Bispectral Index Monitor (Apollo-9000A) is utilized to monitor patients' quantitative consciousness index (qCON) and quantitative nociception index (qNOX).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring of anesthesia depth
Description: During gastroscopy and colonoscopy procedures, the Bispectral Index Monitor (Apollo-9000A) is utilized to monitor patients' quantitative consciousness index (qCON) and quantitative nociception index (qNOX).
Study: NCT06778668

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block with bupivacaine only
Description: Patients undergoing laparoscopic cholecystectomy will receive TAP block with bupivacaine only after induction and before the surgical procedure begins.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block with bupivacaine and fentanyl
Description: Patients undergoing laparoscopic cholecystectomy will receive a TAP block with bupivacaine and fentanyl after induction and before the surgical procedure begins
Study: NCT05126992

Intervention type: BIOLOGICAL
Intervention: AZD1222
Description: Covid-19 AstraZeneca Vaccine
Study: NCT06777992

Intervention type: OTHER
Intervention: Home topographic scans
Description: Patients randomized to the Intervention arm of the trial will additionally use Momentum SpineTM assessment from home at 2-month intervals. If a progression is detected using Momentum SpineTM the participant will be promptly invited to acquire a second set of scans for confirmation. In case of confirmation of the progression using the images from the repeated scans, the scan results will be sent to their local orthopedic surgeon.
Study: NCT06778265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UX-DA001
Description: UX-DA001 (Human Midbrain Dopaminergic Progenitor Cells) is used for treating patients with iPD via implanting into bilateral putamina under stereotactic neurosurgery.~Two dose levels will be planned. Each patient only receives one corresponding dose of UX-DA001.
Study: NCT06778135

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary implatation of large-scale intracranial electrode.
Description: The Neuropixels probe (imec, Leuven, Belgium) is a new high resolution multi electrode technology that uses custom 130-nm complementary metal-oxide-semiconductor fabrication with high surface area but low-impedance titanium nitride recordings to produce high site count devices with extreme electrode density in a small package.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain electrode
Description: Show that Neuropixels can safely and effectively record from large populations of neurons.
Study: NCT06777836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalised Discharge training
Description: Discharge education also contributes to the empowerment of diabetic surgery patients in diabetes management. During the training process, patients will be informed about blood glucose control, diet, exercise and medication management.
Study: NCT06777732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keverprazan
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keverprazan
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keverprazan
Description: Potassium-competitive acid blocker

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Bismuth Pectin
Description: Gastric mucosal protectant
Study: NCT06778733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphane citrate
Description: Clomiphene citrate 100mg/day from day 3 to day 7 of the cycle (5 days) will be added to the low-dose (150 IU) short GnRh antagonist protocol (recombinant human Follicle-Stimulating Hormone (r-FSH-alfa) (Gonal-f; Merck Serono Hellas AE))

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human Follicle-Stimulating Hormone (r-FSH-alfa)
Description: All patients will undergo ovarian stimulation with the standard-dose GNRH-antagonist protocol.~Ovarian stimulation will be initiated with 150 IU of of recombinant human Follicle-Stimulating Hormone (r-FSH-alfa) (Gonal-f; Merck Serono Hellas AE)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human Follicle-Stimulating Hormone (r-FSH-alfa)
Description: All patients will undergo ovarian stimulation with the standard-dose GNRH-antagonist protocol.~Ovarian stimulation will be initiated with 150 IU of of recombinant human Follicle-Stimulating Hormone (r-FSH-alfa) (Gonal-f; Merck Serono Hellas AE)
Study: NCT05772468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality ('VRelax' VR system)
Description: The intervention group 1 will be wearing the 'VRelax' Virtual Reality system during the wound care moment in addition to the standard procedure. The VR system consists of Virtual Reality glasses, and a headphone. The VRelax Application will be used.
Study: NCT04117295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carmat Total Artificial Heart
Description: Heart replacement therapy
Study: NCT06215261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylone
Description: Methylone capsules, given orally, once a week for 3 weeks (Part A) or 4 weeks (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylone
Description: Methylone capsules, given orally, once a week for 3 weeks (Part A) or 4 weeks (Part B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylone
Description: Methylone capsules, given orally, once a week for 3 weeks (Part A) or 4 weeks (Part B)
Study: NCT05890976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive semaglutide tablets orally once daily for 44 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide Placebo
Description: Participants will receive placebo matched to semaglutide.
Study: NCT05045430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver II Non-Woven Dressing
Description: Assigned interventions Subjects will undergo treatment of their chronic and acute wounds as indicated in instructions for use with Silver II Non-Woven dressings.~Subjects will be evaluated as follows:~Full Patient and wound assessment, Informed consent. Wound Assessment, application of dressings, (At each scheduled dressing change.) Wound Assessment, removal of dressings, (At each scheduled dressing change.) The patients will be evaluated at each dressing change over six-week period (per Advanced Medical Solution Product) or until the wound is healed to extent that the use of Silver II Non-Woven dressing is no longer indicated from the time that the patient has been recruited.~The assessment of the presence and reduction of the signs and symptoms of Infection.
Study: NCT04531280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home hospital care
Description: Patients receive hospital-level care in their home.
Study: NCT05885880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue-button screening
Description: Patients will be screened for clinical trial matches using the Blue-button tool
Study: NCT06426381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Asymmetric energy fields can be balanced using the therapeutic touch method and treatment becomes easier. In this way, the person regains his health or can be helped to regain his health.
Study: NCT04696042

Intervention type: DRUG
Intervention: Lanreotide autogel
Description: Lanreotide autogel 90-120 mcg, every 4 weeks
Study: NCT06233110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib will be administered as part of the initial dose escalation cohort and then two candidate doses will be identified to be administered for the safety expansion cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib will be administered as part of the initial dose escalation cohort and then two candidate doses will be identified to be administered for the safety expansion cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib will be administered as part of the initial dose escalation cohort and then two candidate doses will be identified to be administered for the safety expansion cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib will be administered as part of the initial dose escalation cohort and then two candidate doses will be identified to be administered for the safety expansion cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib will be administered as part of the initial dose escalation cohort and then two candidate doses will be identified to be administered for the safety expansion cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib will be administered as part of the initial dose escalation cohort and then two candidate doses will be identified to be administered for the safety expansion cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 10mg BID will be administered in combination with Fostamatinib in each of the study arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 10mg BID will be administered in combination with Fostamatinib in each of the study arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 10mg BID will be administered in combination with Fostamatinib in each of the study arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 10mg BID will be administered in combination with Fostamatinib in each of the study arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 10mg BID will be administered in combination with Fostamatinib in each of the study arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 10mg BID will be administered in combination with Fostamatinib in each of the study arms.
Study: NCT06354686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS Tolerability
Description: The primary objective is to characterize the tolerability of TMS by scalp location (over parietal, motor, modified Beam F3 prefrontal, THREE-D prefrontal, orbitofrontal, and medial prefrontal) and stimulation parameters (single pulse, 10 Hz, theta burst). The secondary objective is to evaluate the feasibility of the knee as a surrogate location to safely trial TMS parameters.
Study: NCT03794726

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic Molar Protraction and PAOO
Description: Molar Protraction with Orthodontic Tooth Movement and Adjunctive Periodontally Accelerated Osteogenic Orthodontics (PAOO) Surgery was performed on all study sites in this arm in coordination with standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic Molar Protraction
Description: Standard orthodontic molar protraction using traditional bands/brackets and orthodontic wires.
Study: NCT05858905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravascular Lithotripsy
Description: The Shockwave Medical IVL System is intended for lithotripsy-enhanced treatment of lesions, including calcified lesions, to increase luminal diameter, allowing for further treatment (e.g. post-dilatation) in the peripheral arterial vasculature. Not for use in the coronary or cerebral vasculature.
Study: NCT04381195

Intervention type: DIAGNOSTIC_TEST
Intervention: REALS Development
Description: Complete drafting of an item pool (adults with ASD, parents, adult service providers); Assign items to all parts of our conceptual framework to ensure sufficient construct coverage across employment, social, and independent living domains; and Conduct cognitive interviews with 25 caregivers of adults with ASD and 25 self-reporting adults with ASD.

Intervention type: DIAGNOSTIC_TEST
Intervention: REALS Testing
Description: A national sample of proxy reporters (e.g., parents, clinicians, group home staff) for 1000 autistic adults and self-reporting autistic adults and adults with other IDD will complete the REALS draft items and a co-calibration battery to establish psychometrics, generate short-forms, and ensure applicability across adults with ASD.
Study: NCT06079281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1850
Description: ALXN1850 will be administered via subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered via SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered via SC injection.
Study: NCT05739981

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m2 IV

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Carboplatin AUC 5-6 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5-6 IV

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: \[1\] Cycle 1, \[2\] the last cycle of neoadjuvant therapy immediately preceding ICS, and \[3\] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: BEV 15 mg/kg IV administration will be included with each cycle EXCEPT the following cycles: \[1\] Cycle 1, \[2\] the last cycle of neoadjuvant therapy immediately preceding ICS, and \[3\] the first cycle of adjuvant chemotherapy (i.e., first cycle after ICS). During the maintenance phase, BEV 15 mg/kg will be administered every 3 weeks as a single agent until disease progression or unacceptable toxicity for a maximum of an additional 18 cycles. In total, BEV may be administered up to 24 cycles. FDA approved BEV biosimilars may be used in this study in place of BEV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMNN-001
Description: IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer
Study: NCT06484075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suvorexant
Description: Drug approved for improving sleep

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be a tablet, but only containing inert inactive ingredients.
Study: NCT04365374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma Tile-Surgically Targeted Radiation Therapy (STaRT)
Description: GammaTiles are a permanently implanted radiation device consisting of Cs-131 seeds positioned within a collagen tile

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiation Therapy
Description: External Beam Radiation Therapy
Study: NCT06256432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Endothelin receptor antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Endothelin receptor antagonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Terlipressin